Skip to content
Nuntius Therapeutics logo

Nuntius Therapeutics

Nuntius Therapeutics is a YC Winter 2021 (W21) company. Based in London, England, United Kingdom. Team of 2.

  • Gene Therapy
  • Nanomedicine

About Nuntius Therapeutics

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Nuntius Therapeutics develops mRNA therapies for patients with cancer, lung disease, and neurodegeneration. Its core technology is a proprietary nanocarrier delivery platform that targets specific tissues and cell types beyond the liver, paired with machine learning models that screen carrier candidates and nucleic acid engineering that boosts protein expression. The platform replaces trial-and-error delivery development and overcomes the cell-targeting limits of current mRNA therapeutics.

Go-to-market

Nuntius Therapeutics partners with pharmaceutical companies to co-develop mRNA therapies, as shown by its collaboration with Taiho Pharmaceutical on cancer applications.

From the Y Combinator listing

How Nuntius Therapeutics describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Cell-specific genetic medicines

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
London, England, United Kingdom
Team size
2
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works